<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455649</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ABR17T</org_study_id>
    <nct_id>NCT01455649</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults</brief_title>
  <official_title>A Prospective, Open-label, Controlled, Randomized Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After 90 to 150 Days After Kidney Transplantation in Adults, Maintaining Corticosteroid and Mycophenolate Sodium Compared to Patients Who Will Maintain the Use of Calcineurin Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deise de Boni Monteiro de Carvalho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Federal de Bonsucesso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy and safety in the use of everolimus,
      with its onset after 3 months of treatment with calcineurin inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient who met the inclusion and exclusion criteria will be included in the study and
      randomized into two groups in the third month post transplant, they will be in use of
      tacrolimus, corticosteroids and Mycophenolate sodium. The group 1 will undergo a conversion
      from calcineurin inhibitor to Everolimus within 1 day (overnight), group 2 will be maintained
      with the initial immunosuppression. We will start Everolimus at 1 mg 2x/day and three days
      after the beginning we will adjust the dose by the serum levels, which will be kept in 6 to
      10ng/dL. The doses of corticosteroids and Mycophenolate sodium will be retained. There will
      be performed renal biopsies at randomization and after 12 months. The glomerular filtration
      rate will be calculated monthly using the MDRD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Creatinine Clearance at 24 months</measure>
    <time_frame>baseline and two years</time_frame>
    <description>The primary objective is to demonstrate the effectiveness and non-inferiority of treatment with everolimus, by assessing renal function, in comparison with the use of calcineurin inhibitor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>baseline and two years</time_frame>
    <description>The secondary objective is to demonstrate the safety by comparing rejection episodes, graft loss, infection, cancer and death in the control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Transplant</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>calcineurin inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcineurin inhibitor</intervention_name>
    <description>Group will maintain their initial immunosuppression therapy with calcineurin inhibitor</description>
    <arm_group_label>calcineurin inhibitor</arm_group_label>
    <other_name>Tacrolimus, Cyclosporin, NeoOral, Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged from 18 to 65 years old

          -  First transplantation recipients

          -  PRA &lt; 30%

          -  Living or cadaveric donor

          -  Stable renal function

          -  Patients not pregnant or breastfeeding , where pregnancy is defined as the woman
             status from conception to gestation conclusion, through a positive beta hCG test
             (&gt;5mUI/mL)

          -  Provided written informed consent form

        Exclusion Criteria:

          -  Cadaveric donor with expanded criterion

          -  Multiple organs transplantation

          -  Kidney cold ischemia time &gt; 24 hours

          -  Severe rejection episode - Banf &gt;IIA

          -  Glomerular filtration rate &lt; 35mL/min

          -  Presence of hard to treat dyslipidemia - severe hypercholesterolemia (&gt;350mg/dL) or
             hypertriglyceridemia (&gt;500mg/dL)

          -  Proteinuria &gt; 800mg/24h

          -  Patients with history of malignancy of any organic system, treated or not, within 5
             years, with or without evidence of local recurrence or metastases, other than
             localized basal cell carcinoma

          -  Female with childbearing potential without using a reliable contraceptive method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco G Miloski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Physician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tereza Matuck, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief of the Nephrology Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regina Sousa</last_name>
    <role>Study Chair</role>
    <affiliation>Head Nurse of The Nephrology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deise BM Carvalho, MD</last_name>
    <phone>+55 (21) 99876059</phone>
    <email>deisebmc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital federal de Bonsucesso</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21041-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>October 19, 2011</last_update_submitted>
  <last_update_submitted_qc>October 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Federal de Bonsucesso</investigator_affiliation>
    <investigator_full_name>Deise de Boni Monteiro de Carvalho</investigator_full_name>
    <investigator_title>Organ Transplant Technical Manager</investigator_title>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>Transplant</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Graft function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

